Spots Global Cancer Trial Database for c225
Every month we try and update this database with for c225 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver | NCT00766220 | Colon Cancer Colorectal Canc... | SIR-spheres Age... Cetuximab Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Sirolimus and Cetuximab in Advanced Malignancies | NCT00940381 | Advanced Cancer | Sirolimus Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Combination With Cetuximab | NCT00895362 | Advanced Cancer... | Erlotinib Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Regorafenib and Cetuximab in Patients With Advanced Malignancy | NCT02095054 | Advanced Cancer... | Regorafenib Cetuximab Questionnaire | 12 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer | NCT00392769 | Endometrial Can... | Cetuximab | - | M.D. Anderson Cancer Center | |
| FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer | NCT00501410 | Colorectal Canc... | 5-FU Cetuximab Dasatinib Leucovorin Oxaliplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Combination With Cetuximab | NCT00895362 | Advanced Cancer... | Erlotinib Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT01427205 | Head and Neck C... | Cetuximab OSI-906 Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | NCT00338039 | Pancreatic Canc... | Cetuximab Gemcitabine Oxaliplatin Capecitabine Radiotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | NCT00338039 | Pancreatic Canc... | Cetuximab Gemcitabine Oxaliplatin Capecitabine Radiotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| Sirolimus and Cetuximab in Advanced Malignancies | NCT00940381 | Advanced Cancer | Sirolimus Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab | NCT00941499 | Advanced Cancer... | HAI Oxaliplatin 5-FU Bevacizumab Cetuximab Leucovorin 5-FU Bevacizumab | - | M.D. Anderson Cancer Center | |
| Sirolimus and Cetuximab in Advanced Malignancies | NCT00940381 | Advanced Cancer | Sirolimus Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | NCT00338039 | Pancreatic Canc... | Cetuximab Gemcitabine Oxaliplatin Capecitabine Radiotherapy | 18 Years - | M.D. Anderson Cancer Center | |
| Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab | NCT00941499 | Advanced Cancer... | HAI Oxaliplatin 5-FU Bevacizumab Cetuximab Leucovorin 5-FU Bevacizumab | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
